Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 23142783
Gulen MF, et al. (2012) Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37, 800-12 23142783
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-1a increase
IRAK4 (human) decrease IRAK4-/-
IL-1a IRAK4 (human) inhibit treatment-induced increase IRAK4-/-
LY294002 IL-1a inhibit treatment-induced increase

T312-p - Akt1 (human)
Modsite: tMKtFCGtPEyLAPE SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T312‑p, Akt1 iso2 (human): T250‑p, Akt1 (mouse): T312‑p, Akt1 (rat): T312‑p, Akt1 (fruit fly): T427‑p, Akt1 (cow): T312‑p
Characterization
Methods used to characterize site in vivo mass spectrometry (in vitro)
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3A (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3A (human)
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-1a increase
IRAK4 (human) decrease IRAK4-/-
IL-1a IRAK4 (human) inhibit treatment-induced increase IRAK4-/-
LY294002 IL-1a inhibit treatment-induced increase

S21-p - GSK3A (human)
Modsite: sGrARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, phospho-antibody, phosphoamino acid analysis, phosphopeptide mapping, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE IKKE (human)
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-1a increase
IRAK4 (human) decrease IRAK4-/-
IL-1a IRAK4 (human) inhibit treatment-induced increase IRAK4-/-
insulin increase
Akt_inhibitor_IV insulin inhibit treatment-induced increase
Akt_inhibitor_IV IL-1a no effect upon treatment-induced increase
IL-1a IKKE (human) inhibit treatment-induced increase Ikbke-/-
IKKE (human) decrease Ikbke-/-

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-1a increase
IRAK4 (human) decrease IRAK4-/-
IL-1a IRAK4 (human) inhibit treatment-induced increase IRAK4-/-
insulin increase
Akt_inhibitor_IV insulin inhibit treatment-induced increase
Akt_inhibitor_IV IL-1a inhibit treatment-induced increase partially attenuated the phosphorylation
IL-1a IKKE (human) inhibit treatment-induced increase Ikbke-/-
IL-1a IKKE (human) inhibit treatment-induced increase Ikbke-/-

T1462-p - TSC2 (human)
Modsite: GLRPRGytISDsAPs SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-1a increase
IRAK4 (human) decrease IRAK4-/-
IL-1a IRAK4 (human) inhibit treatment-induced increase IRAK4-/-
LY294002 IL-1a inhibit treatment-induced increase
Akt_inhibitor_IV IL-1a inhibit treatment-induced increase